The Cancer Letter

Inside information on cancer research and drug development

In Brief

COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

COTA, PreciseDx, and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence-enabled PreciseBreast test that predicts the likelihood of invasive breast cancer recurrence.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account